A Phase II Study of Presurgical Sunitinib in Patients With Metastatic Clear-cell Renal Carcinoma and the Primary Tumor In Situ

Downsizing of primary tumors after 2 cycles of sunitinib is modest but associated with long-term survival. Patients with progression of metastases after pretreatment have short survival and are unlikely to benefit from CN.